

World Journal of *Respirology*

World J Respirol 2013 March 28; 3(1): 1-10



Editorial Board

2011-2015

The *World Journal of Respirology* Editorial Board consists of 148 members, representing a team of worldwide experts in respirology. They are from 38 countries, including Australia (3), Austria (2), Belgium (3), Brazil (1), Bulgaria (1), Canada (5), Chile (1), China (12), Czech Republic (1), Denmark (2), Egypt (5), Ethiopia (1), France (2), Germany (3), Greece (7), Hungary (1), India (6), Ireland (2), Israel (1), Italy (8), Japan (15), Jordan (1), Kuwait (1), Malaysia (1), Poland (1), Portugal (1), Serbia (1), Singapore (2), Slovakia (1), South Africa (1), South Korea (4), Spain (7), Sri Lanka (1), Thailand (1), Tunisia (1), Turkey (4), United Kingdom (5), and United States (33).

EDITOR-IN-CHIEF

Rafael Rosell, *Barcelona*

GUEST EDITORIAL BOARD MEMBERS

Shi-Chuan Chang, *Taipei*
Han-Shui Hsu, *Taipei*
Wu-Huei Hsu, *Taichung*
Jeng-Shing Wang, *Kaohsiung*
Jiu-Yao Wang, *Tainan*
Chuen-Mao Yang, *Taoyuan*

MEMBERS OF THE EDITORIAL BOARD



Australia

Robert James Boots, *Brisbane*
Moyez Jiwa, *Bentley*
Zoe Jane McKeough, *Sydney*



Austria

Bernd Lamprecht, *Salzburg*
Daniel Zimpfer, *Vienna*



Belgium

Teresinha Leal, *Brussels*
Daniel O Rodenstein, *Louvain*
Steven Raphaël Simoens, *Leuven*



Brazil

Marcus V Nora De Souza, *Rio de Janeiro*



Bulgaria

Papantchev Vassil Gueorguiev, *Sofia*



Canada

Kenneth R Chapman, *Toronto*
Abdelilah Soussi Gounni, *Winnipeg*
Vincent Joseph, *Quebec*
Louis P Perrault, *Montreal*
Sat Sharma, *Winnipeg*



Chile

Dante Daniel Cáceres, *Santiago*



China

George G Chen, *Hong Kong*
David Harold Garfield, *Shanghai*
Gang Wang, *Chengdu*
Hui-Ying Wang, *Hangzhou*
Mian Zeng, *Guangzhou*
Wang-Meng Zhao, *Beijing*



Czech Republic

Martina Vasakova, *Praque*



Denmark

Morten Dahl, *Copenhagen*
Nils Milman, *Copenhagen*



Egypt

Mohamed EA Abdelrahim, *Beni Suef*
Yasser Mohamed Amr, *Tanta*
Hatem Yazid El Bawab, *Cairo*
Aliae AR Mohamed-Hussein, *Assiut*
Nirmeen A Sabry, *Cairo*



Ethiopia

Abraham Aseffa, *Addis Ababa*



France

Nawwar Al-Attar, *Paris*
Yves Dominique Durandy, *Massy*



Germany

Martin Kolditz, *Fetscherstr*
Peter Matt, *Switzerland*
Gernot Zissel, *Freiburg*



Greece

Vassilis Aidinis, *Athens*
Demosthenes Bouros, *Alexandroupolis*
Nicos P Hadjiangelis, *Athens*
Chryssi Athanasios Hatzoglou, *Larissa*
Argyris S Michalopoulos, *Athens*
Nikoletta Rovina, *Athens*
Spyros Zakynthinos, *Athens*



Hungary

Balazs Antus, *Budapest*

**India**

Rinti Banerjee, *Mumbai*
 Digambar Behera, *New delhi*
 Dheeraj Gupta, *Chandigarh*
 Anant Mohan, *New Delhi*
 C S Pramesh, *Mumbai*
 Navneet Singh, *Chandigarh*

**Ireland**

Sanjay Haresh Chotirmall, *Dublin*
 Terence O' Connor, *Cork*

**Israel**

Moshe Nimrod Maimon, *Beer-Sheva*

**Italy**

Luigi Bonavina, *Milano*
 Marco Ciotti, *Rome*
 Francesco Dentali, *Busto Arsizio*
 Cesare Gridelli, *Avellino*
 Salvatore Lentini, *Messina*
 Oreste Marrone, *Palermo*
 Giulio Melloni, *Milan*
 Giorgio Pennazza, *Rome*

**Japan**

Jiro Fujita, *Okinawa*
 Satoshi Hagiwara, *Yufu*
 Toyoaki Hida, *Nagoya*
 Genichiro Ishii, *Kashiwa*
 Kyoichi Kaira, *Gunma*
 Hideki Kawai, *Akita*
 Young Hak Kim, *Kyoto*
 Nobuyuki Koyama, *Saitama*
 Tomoshige Matsumoto, *Osaka*
 Toru Mori, *Kyoto*
 Toru Oga, *Kyoto*
 Haruhiko Sugimura, *Hamamatsu*
 Noriaki Sunaga, *Gunma*
 Minoru Takeuchi, *Kyoto*
 Naruo Yoshimura, *Osaka*

**Jordan**

Ahmad Khaled Taleb Darwazah, *Amman*

**Kuwait**

Mohamed Osama Hegazi, *Ahmadi*

**Malaysia**

Cheong-Lieng Teng, *Seremban*

**Poland**

Dariusz Sagan, *Lublin*

**Portugal**

Antonio MF Araujo, *Porto*

**Serbia**

Branislav S Gvozdenovic, *Belgrade*

**Singapore**

Devanand Anantham, *Singapore*
 WS Fred Wong, *Singapore*

**Slovakia**

Ruzena Tkacova, *Kosice*

**South Africa**

John Ndegwa Maina, *Johannesburg*

**South Korea**

Myung-Haing Cho, *Seoul*
 Hyo Sung Jeon, *Deagu*
 Choon-Sik Park, *Gyeonggi-Do*
 Kwang Joo Park, *Masan*

**Spain**

Ramon Fernandez, *Gijon*
 Luis Miguel Seijo Maceiras, *Navarra*
 Antonio Torres Martí, *Barcelona*
 Antonio Pereira-Vega, *Huelva*
 José M Porcel, *Lleida*
 Jose N Sancho-Chust, *Sant Joan d'Alacant*

**Sri Lanka**

Dharmika N Magana-Arachchi, *Kandy*

**Thailand**

Viboon Boonsarngsuk, *Bangkok*

**Tunisia**

Fekri Abroug, *Monastir*

**Turkey**

Cenk Kirakli, *Izmir*
 Murat Ugurlucan, *Istanbul*
 Engin Ulukaya, *Bursa*
 Adnan Yilmaz, *Istanbul*

**United Kingdom**

Jack A Kastelik, *Hull*
 Stephanie Carline Manson, *London*
 John T Murchison, *Edinburgh*
 Stuart Schembri, *Dundee*
 Alice Margaret Turner, *Birmingham*

**United States**

Arjun Bijoy Chatterjee, *Winston-Salem*
 Danny Chu, *Houston*
 Michael E DeBakey, *Texas*
 Steven Mark Donn, *Ann Arbor*
 Raja Michael Flores, *New York*
 Shou-Wei Han, *Atlanta*
 Jia-Peng Huang, *Louisville*
 Farzan Irani, *Cincinnati*
 Dawn Elizabeth Jaroszewski, *Phoenix*
 Lewis J Kaplan, *New Haven*
 Roop K Kaw, *Cleveland*
 Theodoros Kelesidis, *Los Angeles*
 Imran Khalid, *Detroit*
 Amir Maqbul Khan, *Longview*
 James R Klinger, *Providence*
 Zhongmin Li, *Sacramento*
 Rui-Ming Liu, *Birmingham*
 Lan H Ly, *Texas*
 Michael Steven Niederman, *Mineola*
 Gary Frank Nieman, *Syracuse*
 Juan Sanchez-Esteban, *Providence*
 Joseph Ben Shrager, *Stanford*
 Vinit Stéphane, *Madison*
 Xiao Su, *San Francisco*
 Gerald S Supinski, *Lexington*
 Masaaki Tamura, *Manhattan*
 Maged Tanios, *Long Beach*
 Yoshiya Toyoda, *Pittsburgh*
 Terence Trow, *New Haven*
 Alexander D Verin, *Augusta*
 Fa-Di Xu, *Albuquerque*
 Cong Yan, *Indianapolis*
 Joseph B Zwischenberger, *Lexington*



Contents

Four-monthly Volume 3 Number 1 March 28, 2013

BRIEF ARTICLE

- 1 Cytokine gene polymorphisms in idiopathic pulmonary fibrosis
Vasakova M, Sterclova M, Kolesar L, Slavcev A, Skibova J, Langova M, Striz I

CASE REPORT

- 8 Successful management of life-threatening respiratory failure from H1N1 influenza
Al-Attar N, Bouadma L, Altaani H, Wolff M, Nataf P

APPENDIX I-V Instructions to authors

ABOUT COVER Al-Attar N, Bouadma L, Altaani H, Wolff M, Nataf P. Successful management of life-threatening respiratory failure from H1N1 influenza.
World J Respiriol 2013; 3(1): 8-10
<http://www.wjgnet.com/2218-6255/full/v3/i1/8.htm>

AIM AND SCOPE *World Journal of Respiriology* (*World J Respiriol*, *WJR*, online ISSN 2218-6255, DOI: 10.5320) is a peer-reviewed open access (OA) academic journal that aims to guide clinical practice and improve diagnostic and therapeutic skills of clinicians.
WJR covers topics concerning respiratory physiology, respiratory endoscopy, respiratory system tumors, chronic obstructive pulmonary disease, bronchial asthma, respiratory infections, critical respiratory illness, sleep-related respiratory disorders, interstitial lung disease, pulmonary vascular diseases, pulmonary embolism, diagnostic imaging, evidence-based medicine, epidemiology and nursing. The following aspects are covered: Clinical diagnosis, laboratory diagnosis, differential diagnosis, imaging tests, pathological diagnosis, molecular biological diagnosis, immunological diagnosis, genetic diagnosis, functional diagnostics, and physical diagnosis; and comprehensive therapy, drug therapy, surgical therapy, interventional treatment, minimally invasive therapy, and robot-assisted therapy.
We encourage authors to submit their manuscripts to *WJR*. We will give priority to manuscripts that are supported by major national and international foundations and those that are of great basic and clinical significance.

INDEXING/ ABSTRACTING *World Journal of Respiriology* is now indexed in Digital Object Identifier.

FLYLEAF I-II Editorial Board

EDITORS FOR THIS ISSUE

Responsible Assistant Editor: *Xin-Xin Che*
Responsible Electronic Editor: *Shuai Ma*
Proofing Editor-in-Chief: *Lian-Sheng Ma*

Responsible Science Editor: *Xiu-Xia Song*

NAME OF JOURNAL
World Journal of Respiriology

ISSN
ISSN 2218-6255 (online)

LAUNCH DATE
December 30, 2011

FREQUENCY
Four-monthly

EDITOR-IN-CHIEF
Rafael Rosell, MD, PhD, Professor, Chief, Medical Oncology Service, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Ctra Canyet, s/n, 08916 Badalona (Barcelona), Spain

EDITORIAL OFFICE
Jin-Lei Wang, Director
Xiu-Xia Song, Vice Director

World Journal of Respiriology
Room 903, Building D, Ocean International Center, No. 62 Dongsihuan Zhonglu, Chaoyang District, Beijing 100025, China
Telephone: +86-10-85381891
Fax: +86-10-85381893
E-mail: wjrespirol@wjgnet.com
<http://www.wjgnet.com>

PUBLISHER
Baishideng Publishing Group Co., Limited
Flat C, 23/F, Lucky Plaza,
315-321 Lockhart Road, Wan Chai,
Hong Kong, China
Fax: +852-65557188
Telephone: +852-31779906
E-mail: bpgoffice@wjgnet.com
<http://www.wjgnet.com>

PUBLICATION DATE
March 28, 2013

COPYRIGHT

© 2013 Baishideng. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

SPECIAL STATEMENT

All articles published in this journal represent the viewpoints of the authors except where indicated otherwise.

INSTRUCTIONS TO AUTHORS

Full instructions are available online at http://www.wjgnet.com/2218-6255/g_info_20100722180607.htm

ONLINE SUBMISSION

<http://www.wjgnet.com/esp/>

Cytokine gene polymorphisms in idiopathic pulmonary fibrosis

Martina Vasakova, Martina Sterclova, Libor Kolesar, Antonij Slavcev, Jelena Skibova, Martina Langova, Ilja Striz

Martina Vasakova, Martina Sterclova, Department of Respiratory Medicine, 1st Medical School Charles University and Thomayer Hospital, Prague, 14059 Prague 4, Czech Republic
Libor Kolesar, Antonij Slavcev, Ilja Striz, Department of Immunology, Institute for Clinical and Experimental Medicine, Prague, 14021 Prague 4, Czech Republic

Jelena Skibova, Medical Statistic Unit, Institute for Clinical and Experimental Medicine, Prague, 14021 Prague 4, Czech Republic
Martina Langova, Department of Medical Genetics, Thomayer Hospital, Prague, 14059 Prague 4, Czech Republic

Author contributions: Vasakova M designed the study, contributed to the patients' enrolment, evaluated the results, and wrote the paper; Sterclova M coordinated the patients' enrolment, performed the clinical investigations, and collected the data; Kolesar L and Slavcev A performed the immunogenetic investigation and evaluated the results; Skibova J performed the statistical analyses; Langova M provided the consultations in genetics and contributed to writing the manuscript; and Striz I offered the immunology lab for the immunogenetic investigation.

Supported by Grants from the Internal Grant Agency of Ministry of Health of the Czech Republic: 9131-3/2007, NS 10423-3/2009 and NT13433-4/2012

Correspondence to: Martina Vasakova, MD, PhD, Associate Professor, Department of Respiratory Medicine, 1st Medical School Charles University and Thomayer Hospital, Prague, Videnska 800, 14059 Prague 4,

Czech Republic. martina.vasakova@ftn.cz

Telephone: +42-2-61082372 Fax: +42-2-61082206

Received: February 18, 2013 Revised: March 3, 2013

Accepted: March 16, 2013

Published online: March 28, 2013

Abstract

AIM: To characterize cytokine gene polymorphisms in patients with idiopathic pulmonary fibrosis (IPF) compared to healthy controls.

METHODS: Fifty-six IPF patients were involved in the study. The control population consisted of 144 healthy volunteers without history of lung disease.

All of the patients were diagnosed with IPF according to the American Thoracic Society/European Respiratory Society consensus statement. Polymorphisms in the interleukin (*IL*)-1, *IL-1*, *IL-1R*, *IL-1RA*, *IL-2*, *IL-4*, *IL-6*, *IL-10*, *IL-12*, tumour necrosis factor, interferon, transforming growth factor, *IL-1*, *IL-2*, *IL-4* and *IL-4RA* genes were characterized by polymerase chain reaction with sequence-specific primers. Statistical analysis was performed using the MedCalc statistical software. A Bonferroni correction of significance at an alpha of 0.05 was used for multiple analyses. A corrected *P* value less than 0.0023 (0.05/22) was considered significant.

RESULTS: We found significant differences in the *IL-4* promoter region polymorphisms between IPF patients and controls. Namely, polymorphisms of *IL-4* (-590) [computed tomography (CT) in 32 of 56 patients vs 27 of 144 controls; *P* < 0.0001] and *IL-4* (-33) (CT in 25 of 56 patients vs 27 of 144 controls; *P* = 0.0006) differed between both groups. With regard to haplotypes, we found differences in the frequencies for haplotype 1 of *IL-4* (-1098) (-590) (-33) between IPF and controls (TCC in 23 of 56, TTC in 10 of 56, and TTT in 21 of 56 patients vs TCC in 112 of 144, TTC in 0 of 144, and TTT in 32 of 144 controls; *P* < 0.0001). We did not find significant differences in gene polymorphism frequencies of other cytokines in the IPF group vs the controls.

CONCLUSION: We hypothesize that *IL-4* promoter polymorphisms could be involved in the pathogenesis of IPF, likely *via* enhancement of the T_H2 cytokine milieu with exaggerated fibroproliferative healing.

© 2013 Baishideng. All rights reserved.

Key words: Cytokine genes; Idiopathic pulmonary fibrosis; T_H2-type immune response

Core tip: Enhanced fibroproliferation resulting in terminal fibrosis is the main feature of idiopathic pulmonary

fibrosis (IPF). Various mechanisms of alveolar damage and its healing are involved in IPF development. One of the potential contributing pathogenic factors is the genetically encoded imbalance of cytokine production. We found differences between the frequencies of interleukin (*IL*)-4 gene promoter polymorphisms in IPF patients *vs* controls. Based on these results and on the observation that *IL*-4 promoter polymorphisms can influence *IL*-4 production, we hypothesize that *IL*-4 promoter polymorphisms could be involved in the pathogenesis of IPF, likely by enhancing the T_H2 cytokine milieu with subsequent fibroproliferative healing.

Vasakova M, Sterclova M, Kolesar L, Slavcev A, Skibova J, Langova M, Striz I. Cytokine gene polymorphisms in idiopathic pulmonary fibrosis. *World J Respirol* 2013; 3(1): 1-7 Available from: URL: <http://www.wjgnet.com/2218-6255/full/v3/i1/1.htm> DOI: <http://dx.doi.org/10.5320/wjr.v3.i1.1>

INTRODUCTION

Idiopathic pulmonary fibrosis (IPF) is the most severe interstitial lung disease (ILD) and can be characterized by uncontrolled fibroproliferation as a sequelae of the pathological pattern of the healing of multiple alveolar lesions^[1,2]. The role of the regulatory, profibrotic and antifibrotic cytokines and chemokines in the pathogenesis of IPF has been the subject of much conjecture^[3-6]. One of the possible mechanisms of fibroproliferative healing in IPF could be the alternative activation of alveolar macrophages (AM) under the influence of predominantly T_H2-type cytokines. These alternatively activated AMs induce an increase of collagen production by fibroblasts. This process appears to be mediated by C-C chemokine 18, which is overexpressed in the presence of interleukin (*IL*)-10, *IL*-4 and *IL*-13^[7,8]. One of the possible mechanisms of overexpression of T_H2 cytokines is the expression level of redox-sensitive transcription factors. Kikuchi *et al.* observed that the expression of T_H2 cytokines, such as *IL*-4 and *IL*-13, was significantly elevated in the lungs of Nrf2-deficient mice, with an increase in the number of T_H2 cells that expressed the GATA-binding protein 3^[9]. However, the pathogenesis of IPF is a complex, multi-event process in which the T_H2 cytokines might be only one of multiple pathogenic factors. Nevertheless, it seems that cytokine imbalance likely plays an important role in coordinating the healing of alveolar lesions resulting in fibrosis.

One of the mechanisms resulting in increased production of cytokines is a polymorphism in a region of a cytokine gene that causes a change in its expression. Cytokines and their receptors are highly conserved within their coding regions. Although polymorphisms outside of the coding region do not influence the amino acid sequence, they may affect protein expression by influencing alternative mRNA splicing, mRNA stability, or transcription levels. Polymorphisms within the 5'- and 3'-regulatory

regions of cytokines are particularly notable given that they can determine the transcription factor binding sites within the cytokine gene promoters and the structure of enhancers and silencers. In part, individual diversity in immune responses might be explained by such polymorphisms because they result in interindividual differences in the capacity to produce cytokines, which results in a variety of biological consequences. Hence, the investigation of IPF immunogenetics has been focused on identifying the cytokine polymorphisms that contribute to IRF or modify its severity.

Previous studies have described cytokine gene polymorphisms that could possibly be involved in IPF pathogenesis: *IL*-10 (Whittington HA)^[10], *IL*-6 and tumour necrosis factor-receptor (*TNF*-R) II (Pantelidis P)^[11], *IL*-1-receptor antagonist (*RA*) (Whyte M, Korthagen NM, Hutyrova B)^[12-14], transforming growth factor-beta1 (*TGF-β*1) (Xaubet A, Son JY, Awad MR)^[15-17], tumour necrosis factor-alpha (*TNF-α*) (Whyte M, Freeburn RW)^[12,18] and *IL*-8 (Renzoni E, Ahn MH)^[19,20].

In our previous studies, we have suggested the involvement of *IL*-1, *IL*-4, *IL*-12 and interferon (*IFN*)-*γ* gene polymorphisms in the pathogenesis and clinical presentation (functional parameters, bronchoalveolar lavage fluid characteristics, high resolution computed tomography score) of sporadic IPF. Polymorphisms of the promoter region of *IL*-4, which were not previously described in any of the cited studies, were the most significant results^[21-23]. Previous studies have shown that *IL*-4 promoter variants, namely, *IL*-4 (-589) T and *IL*-4 (-33) T, could result in up to three-fold higher transcriptional activity of *IL*-4 *in vitro*, which was subsequently confirmed *in vivo*^[24,25].

In our most recent study, we aimed to reinforce our hypothesis regarding the potential role of cytokine gene polymorphisms, namely, the high-producer *IL*-4 promoter gene polymorphisms, for IPF pathogenesis in a larger number of patients.

MATERIALS AND METHODS

Ethics

The study design and the informed consent form were approved by the Central Ethical Committee of the University Thomayer Hospital and the Institute for Clinical and Experimental Medicine. All patients signed the informed consent form before submitting a blood sample for genotyping.

Study subjects

Fifty-six IPF patients were involved to our study. All patients with IPF were Caucasians [age: mean ± SD (67.29 ± 11.85), range (36-87 years), male/female (37/19)] Patients were diagnosed according to the American Thoracic Society/European Respiratory Society consensus statement^[26]. We used the following criteria: insidious onset of dyspnea, bilateral basal crackles and digital clubbing, restrictive ventilatory pattern and lowered diffusion

Table 1 Demographic and basic clinical parameters of idiopathic pulmonary fibrosis patients, mean ± SD (range)

Parameters	Value
Men:women ratio	37:19
Mean age (yr)	67.29 ± 11.85
Mean FVC (%)	70.96 ± 20.60 (21-127)
TLco (%)	39.78 ± 16.63 (13-81)
BALF LY (%)	17.86 ± 18.93 (0-72)
BALF PMN (%)	15.84 ± 17.58 (1-70)
BALF EOS (%)	3.21 ± 6.95 (0-28)

BALF: Bronchoalveolar lavage fluid; FVC: Forced vital capacity; TLco: Transfer factor for CO; LY: Lymphocytes; PMN: Polymorphonuclear leukocytes; EOS: Eosinophilic leukocytes.

capacity for carbon monoxide, and typical radiological changes on high resolution tomography of the lungs (HRCT) with prevailing fibrotic changes and granulocytic bronchoalveolar lavage (BAL). A videothoracoscopic lung biopsy was performed in 16 patients who did not meet all above-mentioned criteria, and in all cases, the histopathological investigation revealed changes characteristic for usual interstitial pneumonia (UIP). We excluded other potential causes of ILD that can present with a UIP HRCT pattern, namely, hypersensitivity pneumonitis and connective tissue diseases (Table 1).

The control population of 144 unrelated individuals (24 males, 120 females) was made up of Caucasians from the Czech Republic. All control subjects were potential bone marrow donors in generally good health status, without any known diseases, at the time of the study. They did not state asthma, pulmonary fibrosis and systemic inflammatory disease in their histories. The normal controls had a mean age of 43.1 (SD = 16.17) years (range 19-80 years).

Methods

Polymorphisms in the promoter regions of *IL-1α*, *IL-1β*, *IL-1R*, *IL-1RA*, *IL-2*, *IL-4*, *IL-6*, *IL-10*, *IL-12*, *TNF-α* and *IFN-γ* and the polymorphisms in the translated regions of the *TGF-β*, *IL-1β*, *IL-2*, *IL-4* and *IL-4RA* genes were characterized (Table 2).

DNA extraction

Two milliliter of peripheral venous blood were collected into ethylen-diamino-tetraacetic acid (EDTA) tubes. Isolation of genomic DNA was performed from 350 μL of blood using a DNA Blood Kit Cartridge B350 (Qiagen, Germany) on an automated BioRobot EZ1 instrument. The quality of DNA samples was checked on a spectrophotometer and DNA samples were archived at -20 °C.

Cytokine genotyping: We evaluated the polymorphisms of thirteen different cytokine genes utilizing the CYTOKINE GENOTYPING KIT (DynaL, Biotech, Norway). The test is designed as a polymerase chain reaction (PCR) with sequence-specific primers. In detail, each well of a 48-well tray contains a specific primer pair for amplifying

Table 2 List of investigated cytokine gene polymorphisms

Polymorphism	Genotype
<i>IL-1α</i> (-889)	C/C C/T T/T
<i>IL-1β</i> (-511)	C/C C/T T/T
<i>IL-1β</i> (+3962)	C/C C/T T/T
<i>IL-1R pst</i> 1970	C/C C/T T/T
<i>IL-1 RA mspa</i> 11100	C/C C/T T/T
<i>IL-1 RA</i> (+1902)	A/A A/G G/G
<i>IL-12</i> (-1188)	A/A A/C C/C
<i>INF-β</i> UTR 5644	A/A A/T T/T
<i>TGF-β1 codon</i> 10	C/C C/T T/T
<i>TGF-β1 codon</i> 25	C/C C/G G/G
<i>TNF-α</i> (-308)	A/A A/G G/G
<i>TNF-α</i> (-238)	A/A A/G G/G
<i>IL-2</i> (-330)	G/G G/T T/T
<i>IL-2</i> (+166)	G/G G/T T/T
<i>IL-4</i> (-1098)	G/G G/T T/T
<i>IL-4</i> (-590)	C/C C/T T/T
<i>IL-4</i> (-33)	C/C C/T T/T
<i>IL-6</i> (-174)	C/C C/G G/G
<i>IL-6</i> (+565)	A/A A/G G/G
<i>IL-10</i> (-1082)	A/A A/G G/G
<i>IL-10</i> (-819)	C/C C/T T/T
<i>IL-10</i> (-592)	A/A A/C C/C

IL: Interleukin; TNF: Tumor necrosis factor; INF: Interferon; UTR: Untranslated region.

the desired unique sequence. The entire procedure was performed according to the manufacturer’s manual. The obtained pattern of positive and negative PCR was documented and interpreted according to the manufacturer’s worksheet.

Statistical analysis

The basic statistical characteristics, *i.e.*, the mean values and SD, were calculated for continuous variables (demographic and basic clinical parameters). The genotype frequencies and allele carriage frequencies in IPF were determined by direct counting and were compared with those in the control population using a Fisher’s exact or χ^2 test. A Bonferroni correction of significance level at an alpha of 0.05 was used for multiple analyses. Statistical analysis was performed using the MedCalc statistical software. A *P* value less than 0.0023 (0.5/22) was considered significant.

RESULTS

Demographic and clinical data of the IPF group

The statistical analysis of the basic demographic data, functional parameters, and BAL fluid cell counts of the group of IPF patients is presented in Table 1.

Frequencies of cytokine gene polymorphisms in the IPF vs control group

When comparing the frequencies of gene polymorphisms between IPF individuals and controls, we found significant differences for the investigated *IL-4* promoter region polymorphisms (-590) and (-33) (*P* < 0.0001; *P* = 0.0006, respectively). In the IPF group, we more fre-

Table 3 *IL-4* (-590), *IL-4* (-33) and *IL-4* haplotype 1 polymorphisms in idiopathic pulmonary fibrosis and healthy controls *n* (%)

Locus	Genotype	Controls	IPF group	<i>P</i> value
<i>IL-4</i> (-590)	CC	112 (77.8)	24 (42.9)	< 0.0001
	CT	27 (18.8)	31 (55.4)	
	TT	5 (3.5)	1 (1.8)	
<i>IL-4</i> (-33)	CC	112 (77.8)	29 (52.7)	0.0006
	CT	27 (18.8)	25 (45.5)	
	TT	5 (3.5)	1 (1.8)	
<i>IL-4</i> haplotype 1	GCC	0 (0.0)	1 (1.8)	< 0.0001
	TCC	112 (77.8)	23 (41.1)	
	TCT	0 (0.0)	1 (1.8)	
	TTC	0 (0.0)	10 (17.9)	
	TTT	32 (22.2)	21 (37.5)	

IPF: Idiopathic pulmonary fibrosis; IL: Interleukin.

quently observed the T allele at these positions (Table 3).

With regard to haplotypes, we observed differences in the frequency of haplotype 1 in the promoter region of *IL-4* (-1098) (-590) (-33) between the IPF and control groups (haplotype 1: TCC in 23 of 56 (41.1%), TTC in 10 of 56 (17.9%), and TTT in 21 of 56 (37.5%) patients *vs* TCC in 112 of 144 (77.8%), TTC in 0 of 144 (0%), and TTT in 32 of 144 (22.2%) controls; *P* < 0.0001) (Table 3).

The differences in the frequency of haplotype 2 in the promoter region of *IL-4* between IPF and controls were not significant after Bonferroni correction (Haplotype 2: GCC in 16 of 56 (28.6%), GCT in 2 of 56 (2.6%) and TCC in 35 of 56 (62.4%) patients *vs* GCC in 22 of 144 (15.3%), GCT in 0 of 144 (0%) and TCC in 117 of 144 (81.2%) controls; *P* = 0.0061). We also observed differences between IPF and controls for the frequencies of haplotype 1 polymorphisms at *IL-6* (-174) and (*rs565*), but these differences could not be declared as significant after Bonferroni correction [CA in 4 of 56 (7.1%) patients *vs* in 25 of 144 (17.4%) controls; *P* = 0.0438].

We did not find significant differences in gene polymorphisms frequencies for any other cytokines in the IPF group compared to the healthy population.

Hardy-Weinberg equilibrium

We tested for Hardy-Weinberg (HW) equilibrium for all examined SNPs as well. With the exception of *IL-4* (-590) and (-33), all SNPs were in equilibrium. We had to reject HW equilibrium in the control group for both *IL-4* (-590) and *IL-4* (-33) at *P* = 0.05 and in the IPF group for *IL-4* (-590) at *P* = 0.01 and for *IL-4* (-33) at *P* = 0.07. The less significant *P* value in the IPF group for *IL-4* (-33) was because of the smaller number of samples in that group compared to controls.

DISCUSSION

In our study, we have reinforced our hypothesis that *IL-4* gene promoter polymorphisms might be involved in IPF pathogenesis. The involvement of *IL-4* promoter

gene polymorphisms has previously been shown to be involved in the pathogenesis of other diseases and their presentations, including: asthma severity, common variable immune deficiency, autoimmune thyroid disease, atopy, allergic rhinitis, eczema, Crohn's disease and renal transplantation outcome^[27-29]. However, *IL-4* promoter gene polymorphisms have not yet been investigated, to our knowledge, in IPF Individuals who carry the T allele at the (-590) position of the *IL-4* gene, as more than half of our IPF patients did, were previously found to have a higher proportion of IL-4-producing T-helper cells (Nakashima H)^[25]. IL-4 is required for the subsequent appearance of IL-4-producing cells, and thus for T_H2 lineage commitment. Regarding the biological effect of IL-4, RNA hybridization studies have demonstrated that IL-4 suppresses the expression of T_H1 and inflammatory cytokines (IL-1, IL-1 and TNF). These results suggest that IL-4 modulates monocyte production of TNF and IL-1 by down-regulating gene expression. This unique property of IL-4 may be important in regulating the immune response^[30]. Regarding the direct role of IL-4 in the pathogenesis of fibrosis, *in vitro* studies have shown that this cytokine can regulate fibroblast function, including chemotaxis, proliferation, collagen synthesis, and myofibroblast differentiation^[31,32]. In accordance with these observations, other reports have observed increased IL-4 expression in bleomycin-, silica- and radiation-induced lung injuries and suggested that activated macrophages represent the major source of IL-4 during the establishment of active lung fibrosis. In human studies, the progression of IPF was also shown to be associated with sustained IL-4 production^[33-35]. These results strongly suggest that *IL-4* gene polymorphisms with consequent IL-4 overproduction are involved in the pathogenesis of many diseases in which the role of T_H1/T_H2 equilibrium is crucial. IPF is one such disease, and our study supports the hypothesis of an encoded genetic predisposition for T_H2 immune response to environmental stimuli, which could result in alternative activation of AMs and the triggering of pathologic healing of alveolar lesions^[8]. *IL-4* promoter variants, namely, *IL-4* (-589) T and *IL-4* (-33) T, result in up to three-fold higher transcriptional activity *in vitro*, which likely results in increased IL-4 production and thus T_H2 dominant cytokine milieu^[25]. We have found in our study that this high-producer *IL-4* genotype is significantly more present in IPF patients than controls. Aside from the potential direct role of *IL-4* gene polymorphisms in IPF aetiology, these polymorphisms could also have disease-modifying effects. This notion was hypothesized in our previous studies on the correlation of clinical parameters of IPF with *IL-4* gene polymorphisms, in which we put forth the suggestion of the protective role of *IL-4* (-33) CC homozygosity (the low-producer genotype) against the progression of HRCT interstitial changes^[22].

The *IL-6* (-174) G→C polymorphisms were previously mentioned in relationship with IPF development in the two studies by Pantelidis *et al.*^[11] and Riha *et al.*^[36]. In our

study, the statistical significance for the difference of frequencies of this polymorphism between IPF and control individuals was not reached after Bonferroni correction. This is likely because of our investigation of a greater number of polymorphisms in one kit and because the correction for multiple comparisons substantially influenced the result. The *IL-6* (-174) G→C polymorphism appears to be functionally relevant and codes for higher IL-6 production (allele G), which was shown in neonates and later in patients with liver cirrhosis and hepatocellular carcinoma^[26,37]. The role of IL-6 in the pathogenesis of fibrosing interstitial lung diseases has been hypothesized in recent studies, which supports the potential involvement of *IL-6* polymorphisms in the pathogenesis of IPF^[38-40].

Cytokine gene polymorphisms and cytokine milieu are only a part of the net of potential mechanisms and factors leading from alveolar epithelial injuries to pathological fibroproliferative healing and eventual fibrosis. Chemokines, reactive oxygen species, antioxidants, transcription factors, growth factors and enzymes (particularly metalloproteinases and their inhibitors) are also known to be involved.

We are aware that our group of patients is not large compared to other genetic studies, but IPF is a rare disease and our study was performed at one center. We also recognize that the control and IPF patient group differ in sex and age and that this variation could influence our results. This is because IPF is more prevalent in men, not because of the sampling. Nevertheless, there are not any data in the literature on the influence of age and sex on genetic polymorphisms of cytokines, and we posit that the occurrence of cytokine polymorphisms might not be influenced by these variables.

When considering the influence of HW equilibrium, we found disequilibrium for *IL-4* (-590) and for *IL-4* (-33) in both the control and the IPF groups. The deviation from HW equilibrium is likely because we cannot expect Mendelian inheritance in the Czech population as in other European populations. We suggest that the influence of migration, random mutations, selection pressure and non-panmixia is similar for both populations, *i.e.*, our IPF and control group. Therefore, we consider our results as significant despite the suboptimal size of our cohorts from the genetic perspective^[41]. Optimally, multi-centre studies of the effect of cytokine genetic polymorphisms in IPF will be required to support our findings.

COMMENTS

Background

Idiopathic pulmonary fibrosis (IPF) is a serious primary fibrosing interstitial lung disease with an aetiology that is not known to date. Multiple pathogenic pathways and factors contribute to the pathological pattern of healing of alveolar damage in the lungs of individuals with IPF. One of the predisposing factors that are responsible for IPF development is likely the genetically encoded type of immune response, *i.e.*, cytokine gene polymorphisms. Polymorphisms of the cytokine genes, namely, that of T₂-type cytokines, can cause an imbalance in the cytokine milieu with T₂ prevalence, which can then contribute to triggering fibroproliferative healing in the lungs.

Research frontiers

Knowledge of the processes contributing to the development of lung fibrosis could help find a way to influence the pathways involved in IPF pathogenesis. Thus, research of the mechanisms and factors of fibroproliferative healing in the lungs helps to find potential new drugs for treatment of this serious disease.

Innovations and breakthroughs

Previous studies of the immunogenetics of IPF revealed some cytokine gene polymorphisms that could potentially be involved in fibroproliferative healing. Namely, genetic polymorphisms of transforming growth factor, tumor necrosis factor, interleukin (*IL*)-1RN, *IL-6* and *IL-8* might be involved in IPF pathogenesis. The authors believe that T₂ prevalent cytokine milieu could be caused by increased production of IL-4 through its polymorphisms. The authors' previous study on 30 patients with IPF suggested involvement of *IL-4* genetic polymorphisms in IPF development. The authors' studies have shown that *IL-4* polymorphisms, namely, at loci causing higher expression of the cytokines, could be related to more severe fibrotic changes in IPF and also influence chemokine milieu in the lungs. In this study, they have tested the frequencies of cytokine gene polymorphisms in an extended group of IPF patients to further support their previous findings.

Applications

The results support a reason to investigate genetic polymorphisms in patients with IPF to find patients whose enhanced fibroproliferation in the lung could be driven by increased expression of T₂ cytokines, namely, *IL-4*. This subgroup of IPF patients might profit from treatment to block the *IL-4* pathogenetic pathway.

Terminology

The polymorphisms of the genes indicate that some loci are variable, and different individuals and populations can bear different alleles. These different alleles can cause changes in expression of the gene, *i.e.*, influence the production of the cytokine and cause changes in cytokine milieu.

Peer review

This study reported on significant differences in polymorphisms in the *IL-4* and *IL-6* promoter regions between IPF patients and controls. This study is an extension of prior work in a larger cohort of IPF patients and presents novel and important results. The article covers a topic of clinical relevance and novelty. Their findings could have future implications in understanding the pathogenesis of IPF and its treatments. The article is well structured and presents no ethical problems.

REFERENCES

- 1 Lukacs NW, Hogaboam C, Chensue SW, Blease K, Kunkel SL. Type 1/type 2 cytokine paradigm and the progression of pulmonary fibrosis. *Chest* 2001; **120**: 5S-8S [PMID: 11451879 DOI: 10.1378/chest.120.1_suppl.5S]
- 2 Cook DN, Brass DM, Schwartz DA. A matrix for new ideas in pulmonary fibrosis. *Am J Respir Cell Mol Biol* 2002; **27**: 122-124 [PMID: 12151302]
- 3 Kelly M, Kolb M, Bonniaud P, Gauldie J. Re-evaluation of fibrogenic cytokines in lung fibrosis. *Curr Pharm Des* 2003; **9**: 39-49 [PMID: 12570673 DOI: 10.2174/1381612033392341]
- 4 du Bois RM. The genetic predisposition to interstitial lung disease: functional relevance. *Chest* 2002; **121**: 14S-20S [PMID: 11893655 DOI: 10.1378/chest.121.3_suppl.14S-a]
- 5 Barth RK, Hanchett LA, Baecher-Allan CM. Mapping susceptibility genes for the induction of pulmonary fibrosis in mice. *Chest* 2002; **121**: 21S [PMID: 11893659 DOI: 10.1378/chest.121.3_suppl.21S]
- 6 Brody AR, Warshamana GS, Liu JY, Tsai SY, Pociask DA, Brass DM, Schwartz D. Identifying fibrosis susceptibility genes in two strains of inbred mice. *Chest* 2002; **121**: 31S [PMID: 11893670 DOI: 10.1378/chest.121.3_suppl.31S]
- 7 Prasse A, Pechkovsky DV, Toews GB, Junggraithmayr W, Kollert F, Goldmann T, Vollmer E, Müller-Quernheim J, Zissel G. A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18. *Am J Respir Crit Care Med* 2006; **173**: 781-792 [PMID: 16415274 DOI: 10.1164/rccm.200509-1518OC]
- 8 Pechkovsky DV, Prasse A, Kollert F, Engel KM, Dentler J,

- Luttmann W, Friedrich K, Müller-Quernheim J, Zissel G. Alternatively activated alveolar macrophages in pulmonary fibrosis-mediator production and intracellular signal transduction. *Clin Immunol* 2010; **137**: 89-101 [PMID: 20674506 DOI: 10.1016/j.clim.2010.06.017]
- 9 **Kikuchi N**, Ishii Y, Morishima Y, Yageta Y, Haraguchi N, Itoh K, Yamamoto M, Hizawa N. Nrf2 protects against pulmonary fibrosis by regulating the lung oxidant level and Th1/Th2 balance. *Respir Res* 2010; **11**: 31 [PMID: 20298567 DOI: 10.1186/1465-9921-11-31]
- 10 **Whittington HA**, Freeburn RW, Godinho SI, Egan J, Haider Y, Millar AB. Analysis of an IL-10 polymorphism in idiopathic pulmonary fibrosis. *Genes Immun* 2003; **4**: 258-264 [PMID: 12761561 DOI: 10.1038/sj.gene.6363959]
- 11 **Pantelidis P**, Fanning GC, Wells AU, Welsh KI, Du Bois RM. Analysis of tumor necrosis factor-alpha, lymphotoxin-alpha, tumor necrosis factor receptor II, and interleukin-6 polymorphisms in patients with idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med* 2001; **163**: 1432-1436 [PMID: 11371414]
- 12 **Whyte M**, Hubbard R, Meliconi R, Whidborne M, Eaton V, Bingle C, Timms J, Duff G, Facchini A, Pacilli A, Fabbri M, Hall I, Britton J, Johnston I, Di Giovine F. Increased risk of fibrosing alveolitis associated with interleukin-1 receptor antagonist and tumor necrosis factor-alpha gene polymorphisms. *Am J Respir Crit Care Med* 2000; **162**: 755-758 [PMID: 10934117]
- 13 **Korthagen NM**, van Moorsel CH, Kazemier KM, Ruven HJ, Grutters JC. IL1RN genetic variations and risk of IPF: a meta-analysis and mRNA expression study. *Immunogenetics* 2012; **64**: 371-377 [PMID: 22322675 DOI: 10.1007/s00251-012-0604-6]
- 14 **Hutyrová B**, Pantelidis P, Drábek J, Zúrková M, Kolek V, Lenhart K, Welsh KI, Du Bois RM, Petrek M. Interleukin-1 gene cluster polymorphisms in sarcoidosis and idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med* 2002; **165**: 148-151 [PMID: 11790645]
- 15 **Xaubet A**, Marin-Arguedas A, Lario S, Ancochea J, Morell F, Ruiz-Manzano J, Rodriguez-Becerra E, Rodriguez-Arias JM, Inigo P, Sanz S, Campistol JM, Mullol J, Picado C. Transforming growth factor-beta1 gene polymorphisms are associated with disease progression in idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med* 2003; **168**: 431-435 [PMID: 12746254 DOI: 10.1164/rccm.200210-1165OC]
- 16 **Son JY**, Kim SY, Cho SH, Shim HS, Jung JY, Kim EY, Lim JE, Park BH, Kang YA, Kim YS, Kim SK, Chang J, Park MS. TGF-β1 T869C polymorphism may affect susceptibility to idiopathic pulmonary fibrosis and disease severity. *Lung* 2013; **191**: 199-205 [PMID: 23344525 DOI: 10.1007/s00408-012-9447-z]
- 17 **Awad MR**, El-Gamel A, Hasleton P, Turner DM, Sinnott PJ, Hutchinson IV. Genotypic variation in the transforming growth factor-beta1 gene: association with transforming growth factor-beta1 production, fibrotic lung disease, and graft fibrosis after lung transplantation. *Transplantation* 1998; **66**: 1014-1020 [PMID: 9808485 DOI: 10.1097/00007890-199810270-00009]
- 18 **Freeburn RW**, Kendall H, Dobson L, Egan J, Simler NJ, Millar AB. The 3' untranslated region of tumor necrosis factor-alpha is highly conserved in idiopathic pulmonary fibrosis (IPF). *Eur Cytokine Netw* 2001; **12**: 33-38 [PMID: 11282543]
- 19 **Renzoni E**, Lympny P, Sestini P, Pantelidis P, Wells A, Black C, Welsh K, Bunn C, Knight C, Foley P, du Bois RM. Distribution of novel polymorphisms of the interleukin-8 and CXCR1 and 2 genes in systemic sclerosis and cryptogenic fibrosing alveolitis. *Arthritis Rheum* 2000; **43**: 1633-1640 [PMID: 10902769 DOI: 10.1002/1529-0131(200007)]
- 20 **Ahn MH**, Park BL, Lee SH, Park SW, Park JS, Kim DJ, Jang AS, Park JS, Shin HK, Uh ST, Kim YK, Kim YW, Han SK, Jung KS, Lee KY, Jeong SH, Park JW, Choi BW, Park IW, Chung MP, Shin HD, Song JW, Kim DS, Park CS, Shim YS. A promoter SNP rs40731& gt; A in the common allele of the interleukin 8 gene is associated with the development of idiopathic pulmonary fibrosis via the IL-8 protein enhancing mode. *Respir Res* 2011; **12**: 73 [PMID: 21649933 DOI: 10.1186/1465-9921-12-73]
- 21 **Vasakova M**, Striz I, Slavcev A, Jandova S, Kolesar L, Sulc J. Th1/Th2 cytokine gene polymorphisms in patients with idiopathic pulmonary fibrosis. *Tissue Antigens* 2006; **67**: 229-232 [PMID: 16573560 DOI: 10.1111/j.1399-0039.2006.00560.x]
- 22 **Vasakova M**, Striz I, Dutka J, Slavcev A, Jandova S, Kolesar L, Sulc J. Cytokine gene polymorphisms and high-resolution-computed tomography score in idiopathic pulmonary fibrosis. *Respir Med* 2007; **101**: 944-950 [PMID: 17056243 DOI: 10.1016/j.rmed.2006.09.013]
- 23 **Vasakova M**, Striz I, Slavcev A, Jandova S, Dutka J, Terl M, Kolesar L, Sulc J. Correlation of IL-1alpha and IL-4 gene polymorphisms and clinical parameters in idiopathic pulmonary fibrosis. *Scand J Immunol* 2007; **65**: 265-270 [PMID: 17309781 DOI: 10.1111/j.1365-3083.2007.01896.x]
- 24 **Rezaei N**, Aghamohammadi A, Mahmoudi M, Shakiba Y, Kardar GA, Mahmoudi M, Moradi B, Amirzargar AA. Association of IL-4 and IL-10 gene promoter polymorphisms with common variable immunodeficiency. *Immunobiology* 2010; **215**: 81-87 [PMID: 19249119 DOI: 10.1016/j.imbio.2009.01.011]
- 25 **Nakashima H**, Miyake K, Inoue Y, Shimizu S, Akahoshi M, Tanaka Y, Otsuka T, Harada M. Association between IL-4 genotype and IL-4 production in the Japanese population. *Genes Immun* 2002; **3**: 107-109 [PMID: 11960309 DOI: 10.1038/sj.gene.6363830]
- 26 American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). *Am J Respir Crit Care Med* 2000; **161**: 646-664 [PMID: 10673212]
- 27 **Burchard EG**, Silverman EK, Rosenwasser LJ, Borish L, Yandava C, Pillari A, Weiss ST, Hasday J, Lilly CM, Ford JG, Drazen JM. Association between a sequence variant in the IL-4 gene promoter and FEV(1) in asthma. *Am J Respir Crit Care Med* 1999; **160**: 919-922 [PMID: 10471619]
- 28 **Haukim N**, Bidwell JL, Smith AJ, Keen LJ, Gallagher G, Kimberly R, Huizinga T, McDermott MF, Oksenberg J, McNicholl J, Pociot F, Hardt C, D'Alfonso S. Cytokine gene polymorphism in human disease: on-line databases, supplement 2. *Genes Immun* 2002; **3**: 313-330 [PMID: 12209358 DOI: 10.1038/sj.gene.6363881]
- 29 **Cinek O**, Vavrinová P, Striz I, Drevínek P, Sedláková P, Vavrinec J, Slavcev A. Association of single nucleotide polymorphisms within cytokine genes with juvenile idiopathic arthritis in the Czech population. *J Rheumatol* 2004; **31**: 1206-1210 [PMID: 15170937]
- 30 **Essner R**, Rhoades K, McBride WH, Morton DL, Economou JS. IL-4 down-regulates IL-1 and TNF gene expression in human monocytes. *J Immunol* 1989; **142**: 3857-3861 [PMID: 2785566]
- 31 **Postlethwaite AE**, Holness MA, Katai H, Raghov R. Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin 4. *J Clin Invest* 1992; **90**: 1479-1485 [PMID: 1401080 DOI: 10.1172/JCI116015]
- 32 **Sempowski GD**, Beckmann MP, Derdak S, Phipps RP. Subsets of murine lung fibroblasts express membrane-bound and soluble IL-4 receptors. Role of IL-4 in enhancing fibroblast proliferation and collagen synthesis. *J Immunol* 1994; **152**: 3606-3614 [PMID: 7908305]
- 33 **Wallace WA**, Howie SE. Immunoreactive interleukin 4 and interferon-gamma expression by type II alveolar epithelial cells in interstitial lung disease. *J Pathol* 1999; **187**: 475-480 [PMID: 10398109 DOI: 10.1002/(SICI)1096-9896(199903)]
- 34 **Ando M**, Miyazaki E, Fukami T, Kumamoto T, Tsuda T. Interleukin-4-producing cells in idiopathic pulmonary fibrosis:

- an immunohistochemical study. *Respirology* 1999; **4**: 383-391 [PMID: 10612573 DOI: 10.1046/j.1440-1843.1999.00209.x]
- 35 **Huax F**, Liu T, McGarry B, Ullenbruch M, Phan SH. Dual roles of IL-4 in lung injury and fibrosis. *J Immunol* 2003; **170**: 2083-2092 [PMID: 12574379]
- 36 **Riha RL**, Yang IA, Rabnott GC, Tunnicliffe AM, Fong KM, Zimmerman PV. Cytokine gene polymorphisms in idiopathic pulmonary fibrosis. *Intern Med J* 2004; **34**: 126-129 [PMID: 15030461 DOI: 10.1111/j.1444-0903.2004.00503.x]
- 37 **Giannitrapani L**, Soresi M, Giacalone A, Campagna ME, Marasà M, Cervello M, Marasà S, Montalto G. IL-6 -174G/C polymorphism and IL-6 serum levels in patients with liver cirrhosis and hepatocellular carcinoma. *OMICS* 2011; **15**: 183-186 [PMID: 21329460 DOI: 10.1089/omi.2010.0093]
- 38 **De Lauretis A**, Sestini P, Pantelidis P, Hoyles R, Hansell DM, Goh NS, Zappala CJ, Visca D, Maher TM, Denton CP, Ong VH, Abraham DJ, Kelleher P, Hector L, Wells AU, Renzoni EA. Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis. *J Rheumatol* 2013; **40**: 435-446 [PMID: 23378460]
- 39 **O'Donoghue RJ**, Knight DA, Richards CD, Prêle CM, Lau HL, Jarnicki AG, Jones J, Bozinovski S, Vlahos R, Thiem S, McKenzie BS, Wang B, Stumbles P, Laurent GJ, McAnulty RJ, Rose-John S, Zhu HJ, Anderson GP, Ernst MR, Mutsaers SE. Genetic partitioning of interleukin-6 signalling in mice dissociates Stat3 from Smad3-mediated lung fibrosis. *EMBO Mol Med* 2012; **4**: 939-951 [PMID: 22684844 DOI: 10.1002/emmm.201100604]
- 40 **Pedroza M**, Schneider DJ, Karmouty-Quintana H, Coote J, Shaw S, Corrigan R, Molina JG, Alcorn JL, Galas D, Gelinias R, Blackburn MR. Interleukin-6 contributes to inflammation and remodeling in a model of adenosine mediated lung injury. *PLoS One* 2011; **6**: e22667 [PMID: 21799929 DOI: 10.1371/journal.pone.0022667]
- 41 **Nussbaum RL**, McInnes RR, Huntington FW. Thompson and Thompson Genetics in Medicine, Philadelphia, Pennsylvania: W.B.Sounders Company, 2004: 97-109

P- Reviewers Eberlein M, Gernot Z, Wang HY
S- Editor Wen LL **L- Editor** A **E- Editor** Ma S



Successful management of life-threatening respiratory failure from H1N1 influenza

Nawwar Al-Attar, Lila Bouadma, Haitham Altaani, Michel Wolff, Patrick Nataf

Nawwar Al-Attar, Haitham Altaani, Patrick Nataf, Department of Cardiac Surgery, Assistance Publique-Hôpitaux de Paris (AP-HP), Bichat Hospital, 75018 Paris, France

Lila Bouadma, Michel Wolff, Medical Intensive Care Unit, Assistance Publique-Hôpitaux de Paris (AP-HP), Bichat Hospital, 75018 Paris, France

Author contributions: All authors contributed equally to this work; Al-Attar N and Altaani H performed the ECMO procedure, collected and reviewed clinical information about the patient and wrote the report; Bouadma L and Wolff M were involved with daily care at the intensive care unit and assisted with report writing; Nataf P was consulted on management of the patient and assisted with report writing.

Correspondence to: Nawwar Al-Attar, PhD, Professor, Department of Cardiac Surgery, Assistance Publique-Hôpitaux de Paris (AP-HP), Bichat Hospital, 46 rue Henri Huchard, 75018 Paris, France. nawwar.al-attar@bch.aphp.fr

Telephone: +33-1402-57132 Fax: +33-1402-57229

Received: January 08, 2013 Revised: February 18, 2013

Accepted: March 9, 2013

Published online: March 28, 2013

Abstract

We report the outcome of a pregnant woman with a life-threatening acute respiratory distress syndrome from a novel influenza A (H1N1) virus infection 3 d postpartum successfully managed by veno-arterial extracorporeal membrane oxygenation. The patient was successfully weaned from extracorporeal membrane oxygenation (ECMO) on day 10. Novel H1N1 virus infection was identified by real-time reverse transcription-polymerase chain reaction. Veno-arterial ECMO in this patient carried a number of specific advantages namely maintaining haemodynamic stability obviating the need for inotrope support and improving oxygenation compared to alternative approaches such as veno-venous ECMO and pumpless devices. Femoral arterial and venous cannulae were inserted in a pure percutaneous method allowing rapid establishment of extracorporeal circulation. Given the high mortality of acute respiratory

distress syndrome following novel H1N1 virus infection, we advocate the use of ECMO when conventional mechanical ventilation fails.

© 2013 Baishideng. All rights reserved.

Key words: Respiratory failure; Influenza A; Extracorporeal membrane oxygenation; Pregnancy; Outcome

Core tip: Novel influenza A virus infection can result in acute respiratory distress syndrome extremely difficult to manage with conventional mechanical ventilation and non-invasive therapy. Veno-arterial extracorporeal membrane oxygenation can provide respiratory and circulatory support in these patients. We successfully weaned a postpartum patient after 10 d of extracorporeal membrane oxygenation. Furthermore, by employing the pure percutaneous method of cannulae insertion, we minimized implantation time and trauma.

Al-Attar N, Bouadma L, Altaani H, Wolff M, Nataf P. Successful management of life-threatening respiratory failure from H1N1 influenza. *World J Respirol* 2013; 3(1): 8-10 Available from: <http://www.wjgnet.com/2218-6255/full/v3/i1/8.htm> DOI: <http://dx.doi.org/10.5320/wjr.v3.i1.8>

INTRODUCTION

Acute respiratory distress syndrome (ARDS) is a life-threatening complication of influenza. It has been reported after novel influenza A (H1N1) virus infection and is a major cause of death in these patients^[1]. The virus causes lung damage from direct injury to the respiratory epithelium and can be associated with secondary cytokine storm^[1]. The management comprises aggressive supportive care, with positive pressure ventilation and high oxygen concentrations. However, mechanical ventilation carries the risk of barotrauma and oxygen toxicity,




Figure 1 Chest-X ray showing bilateral infiltrates.

further aggravating lung injury^[2]. In a series of ARDS in patients with H1N1 virus infection, mortality among the patients requiring mechanical ventilation was 58%^[11] compared to 30% for other causes of ARDS. A number of adjuvant strategies have been employed for treatment of ARDS, and the use of extracorporeal membrane oxygenation (ECMO) has shown to reduce the ventilator-induced lung injury and mortality in certain patients^[3,4]. The outcome of ECMO has not been specifically reported in patients with ARDS secondary to novel H1N1 virus infection but can improve survival by 50% regardless of the etiology^[5,6].

CASE REPORT

A 41-year-old woman (para 5, gravida 2) was transferred from the department of obstetrics for acute respiratory distress 3 d following a normal vaginal delivery of a 37 wk term baby boy. The previous gynaecological, medical and surgical history were unremarkable. A few days before delivery she had fever (39 °C) and a flu-like illness. On the third post-partum day, the patient developed increasing dyspnoea. This was followed by severe hypoxemia, acute respiratory distress syndrome, and an inability to achieve adequate oxygenation with conventional ventilation modalities (SaO₂ < 90%, arterial pO₂ = 49 mmHg and pCO₂ = 29 mmHg). Her chest X-ray showed bilateral widespread alveolar infiltrates (Figure 1). She had a white cell count of 2.98 × 10⁹/L with predominant neutrophilia (88.6%) and lymphocytosis (10.1%), and C-reactive protein of 179 mg/L. She was transferred to the intensive care unit where orotracheal intubation and advanced mechanical ventilation (fraction of inspired oxygen of 1.0 and positive end-expiratory pressure of 15 cm H₂O including inhaled nitric oxide at 10 PPM) did not significantly improve the respiratory status (SpO₂ < 70%). Consequently, veno-arterial ECMO was established with an 18Fr cannula inserted into the right common femoral artery and a 22Fr venous cannula in the right femoral vein, associated with volume resuscitation. This led to reversal of hypercapnia and improved oxygenation.

The patient was successfully weaned from ECMO on day 10. Bacterial cultures of blood, urine and tracheal

aspirate were negative. Novel H1N1 virus infection was documented by testing of respiratory (bronchoalveolar lavage) specimens with real-time reverse transcription-polymerase chain reaction.

DISCUSSION

The patient was previous healthy and although pregnancy is known to increase the risk for influenza-associated morbidity and mortality during seasonal influenza epidemics^[7,8] and pandemics^[9,10], there seems to be a disproportionate increase in lethality for young, healthy individuals infected with HP strains of H1N1 viruses which correlates with a significant increase in the recruitment of inducible NOS-producing dendritic cells to the pneumonic lung, explaining the severity of the presentation^[11]. The Centers for Disease Control and Prevention have reported a total of 20 cases of novel H1N1 virus infection among pregnant women in the United States, of which one patient developed ARDS and died^[12]. In metropolitan France, 3 cases of infection in pregnant women were reported (out of a total of 921 confirmed or probable cases), none of which were associated with complications^[13]. The use of veno-arterial ECMO in this patient maintained hemodynamic stability obviating the need for inotrope support and is less cumbersome than venovenous ECMO. It was inserted in a pure percutaneous method using the Seldinger's technique allowing rapid establishment of extracorporeal circulation. After puncture of the vessel, a soft tipped guide-wire was passed through the needle. Dilators were passed stepwise over the guide-wire to enlarge the access until the cannula size was achieved. The cannula was inserted and connected to the ECMO system. Thus percutaneous femoral cannulation carries the advantage of allowing an expeditious procedure in an emergency situation^[14]. Because novel H1N1 virus infection complicated by ARDS is associated with a high mortality, ECMO should be considered when conventional mechanical ventilation fails.

REFERENCES

- 1 **Ng WF**, To KF, Lam WW, Ng TK, Lee KC. The comparative pathology of severe acute respiratory syndrome and avian influenza A subtype H5N1--a review. *Hum Pathol* 2006; **37**: 381-390 [PMID: 16564911 DOI: 10.1016/j.humpath.2006.01.015]
- 2 **Ware LB**, Matthay MA. The acute respiratory distress syndrome. *N Engl J Med* 2000; **342**: 1334-1349 [PMID: 10793167 DOI: 10.1017/S0265021508004870]
- 3 **Muellenbach RM**, Kredel M, Wunder C, Küstermann J, Wurmb T, Schwemmer U, Schuster F, Anetseder M, Roewer N, Brederlau J. Arteriovenous extracorporeal lung assist as integral part of a multimodal treatment concept: a retrospective analysis of 22 patients with ARDS refractory to standard care. *Eur J Anaesthesiol* 2008; **25**: 897-904 [PMID: 18662425]
- 4 **Rosamel P**, Delannoy B, Jault V, Metton O, Dubien PY, Flamens C, Bastien O. Refractory infectious ARDS: place of extracorporeal membrane oxygenation. *Ann Fr Anesth Reanim* 2008; **27**: 446-449 [PMID: 18436420 DOI: 10.1016/j.annfar.2008.02.007]
- 5 **Hemmila MR**, Rowe SA, Boules TN, Miskulin J, McGill-

- licuddy JW, Schuerer DJ, Haft JW, Swaniker F, Arbabi S, Hirschl RB, Bartlett RH. Extracorporeal life support for severe acute respiratory distress syndrome in adults. *Ann Surg* 2004; **240**: 595-605; discussion 605-607 [PMID: 15383787]
- 6 **Lewandowski K.** Extracorporeal membrane oxygenation for severe acute respiratory failure. *Crit Care* 2000; **4**: 156-168 [PMID: 11094500 DOI: 10.1186/cc689]
- 7 **Neuzil KM,** Reed GW, Mitchel EF, Simonsen L, Griffin MR. Impact of influenza on acute cardiopulmonary hospitalizations in pregnant women. *Am J Epidemiol* 1998; **148**: 1094-1102 [PMID: 9850132 DOI: 10.1093/oxfordjournals.aje.a009587]
- 8 **Dodds L,** McNeil SA, Fell DB, Allen VM, Coombs A, Scott J, MacDonald N. Impact of influenza exposure on rates of hospital admissions and physician visits because of respiratory illness among pregnant women. *CMAJ* 2007; **176**: 463-468 [PMID: 17296958 DOI: 10.1503/cmaj.061435]
- 9 **Freeman DW,** Barno A. Deaths from Asian influenza associated with pregnancy. *Am J Obstet Gynecol* 1959; **78**: 1172-1175 [PMID: 13824729]
- 10 **Harris JW.** Influenza occurring in pregnant women. *JAMA* 1919; **72**: 978-980 [DOI: 10.1001/jama.1919.02610140008002]
- 11 **Aldridge JR,** Moseley CE, Boltz DA, Negovetich NJ, Reynolds C, Franks J, Brown SA, Doherty PC, Webster RG, Thomas PG. TNF/iNOS-producing dendritic cells are the necessary evil of lethal influenza virus infection. *Proc Natl Acad Sci USA* 2009; **106**: 5306-5311 [PMID: 19279209 DOI: 10.1073/pnas.0900655106]
- 12 **Centers for Disease Control and Prevention (CDC).** Novel influenza A (H1N1) virus infections in three pregnant women - United States, April-May 2009. *MMWR Morb Mortal Wkly Rep* 2009; **58**: 497-500 [PMID: 19444154]
- 13 Bulletin Epidémiologique Hebdomadaire, Note Dit-InVS : décès A(H1N1) p2009. cited 2009-06-03. Available from: URL: http://opac.invs.sante.fr/doc_num.php?explnum_id=6403
- 14 **Roussel A,** Al-Attar N, Alkhoder S, Radu C, Raffoul R, Alshammari M, Montravers P, Wolff M, Nataf P. Outcomes of percutaneous femoral cannulation for venoarterial extracorporeal membrane oxygenation support. *EHJ: Acute Cardiovascular Care* 2012; **1**: 111-114 [DOI: 10.1177/2048872612449417]

P- Reviewers Kelesidis T, Matsumoto T, O'Connor T, Sancho-Chust JN, Stéphane V **S- Editor** Huang XZ
L- Editor A **E- Editor** Ma S



GENERAL INFORMATION

World Journal of Respirology (*World J Respirol*, *WJR*, online ISSN 2218-6255, DOI: 10.5320) is a peer-reviewed open access (OA) academic journal that aims to guide clinical practice and improve diagnostic and therapeutic skills of clinicians.

Aim and scope

WJR covers topics concerning respiratory physiology, respiratory endoscopy, respiratory system tumors, chronic obstructive pulmonary disease, bronchial asthma, respiratory infections, critical respiratory illness, sleep-related respiratory disorders, interstitial lung disease, pulmonary vascular diseases, pulmonary embolism, diagnostic imaging, evidence-based medicine, epidemiology and nursing. The following aspects are covered: Clinical diagnosis, laboratory diagnosis, differential diagnosis, imaging tests, pathological diagnosis, molecular biological diagnosis, immunological diagnosis, genetic diagnosis, functional diagnostics, and physical diagnosis; and comprehensive therapy, drug therapy, surgical therapy, interventional treatment, minimally invasive therapy, and robot-assisted therapy.

We encourage authors to submit their manuscripts to *WJR*. We will give priority to manuscripts that are supported by major national and international foundations and those that are of great basic and clinical significance.

WJR is edited and published by Baishideng Publishing Group (BPG). BPG has a strong professional editorial team composed of science editors, language editors and electronic editors. BPG currently publishes 41 OA clinical medical journals, and is one of the leading medical publishers, with the first-class editing and publishing capacity and production.

Columns

The columns in the issues of *WJR* will include: (1) Editorial: The editorial board members are invited to make comments on an important topic in their field in terms of its current research status and future directions to lead the development of this discipline; (2) Frontier: The editorial board members are invited to select a highly cited cutting-edge original paper of his/her own to summarize major findings, the problems that have been resolved and remain to be resolved, and future research directions to help readers understand his/her important academic point of view and future research directions in the field; (3) Diagnostic Advances: The editorial board members are invited to write high-quality diagnostic advances in their field to improve the diagnostic skills of readers. The topic covers general clinical diagnosis, differential diagnosis, pathological diagnosis, laboratory diagnosis, imaging diagnosis, endoscopic diagnosis, biotechnological diagnosis, functional diagnosis, and physical diagnosis; (4) Therapeutics Advances: The editorial board members are invited to write high-quality therapeutic advances in their field to help improve the therapeutic skills of readers. The topic covers medication therapy, psychotherapy, physical therapy, replacement therapy, interventional therapy, minimally invasive therapy, endoscopic therapy, transplantation therapy, and surgical therapy; (5) Field of Vision: The editorial board members are invited to write commentaries on classic articles, hot topic articles, or latest articles to keep readers at the forefront of research and increase their levels of clinical research. Classic articles refer to papers that are included in Web of Knowledge and have received a large number of citations (ranking in the top 1%) after being published for more

than years, reflecting the quality and impact of papers. Hot topic articles refer to papers that are included in Web of Knowledge and have received a large number of citations after being published for no more than 2 years, reflecting cutting-edge trends in scientific research. Latest articles refer to the latest published high-quality papers that are included in PubMed, reflecting the latest research trends. These commentary articles should focus on the status quo of research, the most important research topics, the problems that have now been resolved and remain to be resolved, and future research directions. Basic information about the article to be commented (including authors, article title, journal name, year, volume, and inclusive page numbers); (6) Minireviews: The editorial board members are invited to write short reviews on recent advances and trends in research of molecular biology, genomics, and related cutting-edge technologies to provide readers with the latest knowledge and help improve their diagnostic and therapeutic skills; (7) Review: To make a systematic review to focus on the status quo of research, the most important research topics, the problems that have now been resolved and remain to be resolved, and future research directions; (8) Topic Highlight: The editorial board members are invited to write a series of articles (7-10 articles) to comment and discuss a hot topic to help improve the diagnostic and therapeutic skills of readers; (9) Medical Ethics: The editorial board members are invited to write articles about medical ethics to increase readers' knowledge of medical ethics. The topic covers international ethics guidelines, animal studies, clinical trials, organ transplantation, etc.; (10) Clinical Case Conference or Clinicopathological Conference: The editorial board members are invited to contribute high-quality clinical case conference; (11) Original Articles: To report innovative and original findings in respirology; (12) Brief Articles: To briefly report the novel and innovative findings in respirology; (13) Meta-Analysis: To summarize a given quantitative effect, e.g., the clinical effectiveness and safety of clinical treatments by combining data from two or more randomized controlled trials, thereby providing more precise and externally valid estimates than those which would stem from each individual dataset if analyzed separately from the others; (14) Case Report: To report a rare or typical case; (15) Letters to the Editor: To discuss and make reply to the contributions published in *WJR*, or to introduce and comment on a controversial issue of general interest; (16) Book Reviews: To introduce and comment on quality monographs of respirology; and (17) Autobiography: The editorial board members are invited to write their autobiography to provide readers with stories of success or failure in their scientific research career. The topic covers their basic personal information and information about when they started doing research work, where and how they did research work, what they have achieved, and their lessons from success or failure.

Name of journal

World Journal of Respirology

ISSN

ISSN 2218-6255 (online)

Launch date

December 30, 2011

Frequency

Four-monthly

Instructions to authors

Editor-in-chief

Rafael Rosell, MD, PhD, Professor, Chief, Medical Oncology Service, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Ctra Canyet, s/n, 08916 Badalona (Barcelona), Spain

Editorial office

Jin-Lai Wang, Director
Xiu-Xia Song, Vice Director
World Journal of Respiriology
Room 903, Building D, Ocean International Center,
No. 62 Dongsihuan Zhonglu, Chaoyang District,
Beijing 100025, China
Telephone: +86-10-85381891
Fax: +86-10-85381893
E-mail: wjrespirol@wjgnet.com
<http://www.wjgnet.com>

Publisher

Baishideng Publishing Group Co., Limited
Flat C, 23/F, Lucky Plaza,
315-321 Lockhart Road, Wan Chai, Hong Kong, China
Fax: +852-65557188
Telephone: +852-31779906
E-mail: bpgoffice@wjgnet.com
<http://www.wjgnet.com>

Production center

Beijing Baishideng BioMed Scientific Co., Limited
Room 903, Building D, Ocean International Center,
No. 62 Dongsihuan Zhonglu, Chaoyang District,
Beijing 100025, China
Telephone: +86-10-85381892
Fax: +86-10-85381893

Representative office

USA Office
8226 Regency Drive,
Pleasanton, CA 94588-3144, United States

Instructions to authors

Full instructions are available online at http://www.wjgnet.com/2218-6255/g_info_20100722180607.htm

Indexed and abstracted in

Digital Object Identifier

SPECIAL STATEMENT

All articles published in this journal represent the viewpoints of the authors except where indicated otherwise.

Biostatistical editing

Statistical review is performed after peer review. We invite an expert in Biomedical Statistics to evaluate the statistical method used in the paper, including *t*-test (group or paired comparisons), chi-squared test, Ridit, probit, logit, regression (linear, curvilinear, or stepwise), correlation, analysis of variance, analysis of covariance, *etc.* The reviewing points include: (1) Statistical methods should be described when they are used to verify the results; (2) Whether the statistical techniques are suitable or correct; (3) Only homogeneous data can be averaged. Standard deviations are preferred to standard errors. Give the number of observations and subjects (*n*). Losses in observations, such as drop-outs from the study should be reported; (4) Values such as ED50, LD50, IC50 should have their 95% confidence limits calculated and compared by weighted probit analysis (Bliss and Finney); and (5) The word 'significantly' should be replaced by its synonyms (if it indicates extent) or the *P* value (if it indicates statistical significance).

Conflict-of-interest statement

In the interests of transparency and to help reviewers assess any po-

tential bias, *WJR* requires authors of all papers to declare any competing commercial, personal, political, intellectual, or religious interests in relation to the submitted work. Referees are also asked to indicate any potential conflict they might have reviewing a particular paper. Before submitting, authors are suggested to read "Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Ethical Considerations in the Conduct and Reporting of Research: Conflicts of Interest" from International Committee of Medical Journal Editors (ICMJE), which is available at: http://www.icmje.org/ethical_4conflicts.html.

Sample wording: [Name of individual] has received fees for serving as a speaker, a consultant and an advisory board member for [names of organizations], and has received research funding from [names of organization]. [Name of individual] is an employee of [name of organization]. [Name of individual] owns stocks and shares in [name of organization]. [Name of individual] owns patent [patent identification and brief description].

Statement of informed consent

Manuscripts should contain a statement to the effect that all human studies have been reviewed by the appropriate ethics committee or it should be stated clearly in the text that all persons gave their informed consent prior to their inclusion in the study. Details that might disclose the identity of the subjects under study should be omitted. Authors should also draw attention to the Code of Ethics of the World Medical Association (Declaration of Helsinki, 1964, as revised in 2004).

Statement of human and animal rights

When reporting the results from experiments, authors should follow the highest standards and the trial should conform to Good Clinical Practice (for example, US Food and Drug Administration Good Clinical Practice in FDA-Regulated Clinical Trials; UK Medicines Research Council Guidelines for Good Clinical Practice in Clinical Trials) and/or the World Medical Association Declaration of Helsinki. Generally, we suggest authors follow the lead investigator's national standard. If doubt exists whether the research was conducted in accordance with the above standards, the authors must explain the rationale for their approach and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study.

Before submitting, authors should make their study approved by the relevant research ethics committee or institutional review board. If human participants were involved, manuscripts must be accompanied by a statement that the experiments were undertaken with the understanding and appropriate informed consent of each. Any personal item or information will not be published without explicit consents from the involved patients. If experimental animals were used, the materials and methods (experimental procedures) section must clearly indicate that appropriate measures were taken to minimize pain or discomfort, and details of animal care should be provided.

SUBMISSION OF MANUSCRIPTS

Manuscripts should be typed in 1.5 line spacing and 12 pt. Book Antiqua with ample margins. Number all pages consecutively, and start each of the following sections on a new page: Title Page, Abstract, Introduction, Materials and Methods, Results, Discussion, Acknowledgements, References, Tables, Figures, and Figure Legends. Neither the editors nor the publisher are responsible for the opinions expressed by contributors. Manuscripts formally accepted for publication become the permanent property of Baishideng Publishing Group Co., Limited, and may not be reproduced by any means, in whole or in part, without the written permission of both the authors and the publisher. We reserve the right to copy-edit and put onto our website accepted manuscripts. Authors should follow the relevant guidelines for the care and use of laboratory animals of their institution or national animal welfare committee. For the sake of transparency in regard to the performance and reporting of clinical trials, we endorse the policy of the ICMJE to refuse to publish papers on clinical trial results if the trial was not recorded in a publicly-accessible registry at its outset. The only register now available, to our knowledge, is <http://www.clinicaltrials.gov> sponsored

by the United States National Library of Medicine and we encourage all potential contributors to register with it. However, in the case that other registers become available you will be duly notified. A letter of recommendation from each author's organization should be provided with the contributed article to ensure the privacy and secrecy of research is protected.

Authors should retain one copy of the text, tables, photographs and illustrations because rejected manuscripts will not be returned to the author(s) and the editors will not be responsible for loss or damage to photographs and illustrations sustained during mailing.

Online submissions

Manuscripts should be submitted through the Online Submission System at: <http://www.wjgnet.com/esps/>. Authors are highly recommended to consult the ONLINE INSTRUCTIONS TO AUTHORS (http://www.wjgnet.com/2218-6255/g_info_20100722180607.htm) before attempting to submit online. For assistance, authors encountering problems with the Online Submission System may send an email describing the problem to wjrespirol@wjgnet.com, or by telephone: +86-10-85381892. If you submit your manuscript online, do not make a postal contribution. Repeated online submission for the same manuscript is strictly prohibited.

MANUSCRIPT PREPARATION

All contributions should be written in English. All articles must be submitted using word-processing software. All submissions must be typed in 1.5 line spacing and 12 pt. Book Antiqua with ample margins. Style should conform to our house format. Required information for each of the manuscript sections is as follows:

Title page

Title: Title should be less than 12 words.

Running title: A short running title of less than 6 words should be provided.

Authorship: Authorship credit should be in accordance with the standard proposed by ICMJE, based on (1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; (2) drafting the article or revising it critically for important intellectual content; and (3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3.

Institution: Author names should be given first, then the complete name of institution, city, province and postcode. For example, Xu-Chen Zhang, Li-Xin Mei, Department of Pathology, Chengde Medical College, Chengde 067000, Hebei Province, China. One author may be represented from two institutions, for example, George Sgourakis, Department of General, Visceral, and Transplantation Surgery, Essen 45122, Germany; George Sgourakis, 2nd Surgical Department, Korgialenio-Benakio Red Cross Hospital, Athens 15451, Greece

Author contributions: The format of this section should be: Author contributions: Wang CL and Liang L contributed equally to this work; Wang CL, Liang L, Fu JF, Zou CC, Hong F and Wu XM designed the research; Wang CL, Zou CC, Hong F and Wu XM performed the research; Xue JZ and Lu JR contributed new reagents/analytic tools; Wang CL, Liang L and Fu JF analyzed the data; and Wang CL, Liang L and Fu JF wrote the paper.

Supportive foundations: The complete name and number of supportive foundations should be provided, e.g. Supported by National Natural Science Foundation of China, No. 30224801

Correspondence to: Only one corresponding address should be provided. Author names should be given first, then author title, af-

filiation, the complete name of institution, city, postcode, province, country, and email. All the letters in the email should be in lower case. A space interval should be inserted between country name and email address. For example, Montgomery Bissell, MD, Professor of Medicine, Chief, Liver Center, Gastroenterology Division, University of California, Box 0538, San Francisco, CA 94143, United States. montgomerybissell@ucsf.edu

Telephone and fax: Telephone and fax should consist of +, country number, district number and telephone or fax number, e.g. Telephone: +86-10-85381892 Fax: +86-10-85381893

Peer reviewers: All articles received are subject to peer review. Normally, three experts are invited for each article. Decision on acceptance is made only when at least two experts recommend publication of an article. All peer-reviewers are acknowledged on Express Submission and Peer-review System website.

Abstract

There are unstructured abstracts (no less than 200 words) and structured abstracts. The specific requirements for structured abstracts are as follows:

An informative, structured abstract should accompany each manuscript. Abstracts of original contributions should be structured into the following sections: AIM (no more than 20 words; Only the purpose of the study should be included. Please write the Aim in the form of "To investigate/study/...?"), METHODS (no less than 140 words for Original Articles; and no less than 80 words for Brief Articles), RESULTS (no less than 150 words for Original Articles and no less than 120 words for Brief Articles; You should present *P* values where appropriate and must provide relevant data to illustrate how they were obtained, e.g., 6.92 ± 3.86 vs 3.61 ± 1.67 , $P < 0.001$), and CONCLUSION (no more than 26 words).

Key words

Please list 5-10 key words, selected mainly from *Index Medicus*, which reflect the content of the study.

Core tip

Please write a summary of less than 100 words to outline the most innovative and important arguments and core contents in your paper to attract readers.

Text

For articles of these sections, original articles and brief articles, the main text should be structured into the following sections: INTRODUCTION, MATERIALS AND METHODS, RESULTS and DISCUSSION, and should include appropriate Figures and Tables. Data should be presented in the main text or in Figures and Tables, but not in both. The main text format of these sections, editorial, topic highlight, case report, letters to the editors, can be found at http://www.wjgnet.com/2218-6255/g_info_list.htm.

Illustrations

Figures should be numbered as 1, 2, 3, etc., and mentioned clearly in the main text. Provide a brief title for each figure on a separate page. Detailed legends should not be provided under the figures. This part should be added into the text where the figures are applicable. Keeping all elements compiled is necessary in line-art image. Scale bars should be used rather than magnification factors, with the length of the bar defined in the legend rather than on the bar itself. File names should identify the figure and panel. Avoid layering type directly over shaded or textured areas. Please use uniform legends for the same subjects. For example: Figure 1 Pathological changes in atrophic gastritis after treatment. A: ...; B: ...; C: ...; D: ...; E: ...; F: ...; G: ...etc. It is our principle to publish high resolution-figures for the E-versions.

Tables

Three-line tables should be numbered 1, 2, 3, etc., and mentioned clearly in the main text. Provide a brief title for each table. Detailed

Instructions to authors

legends should not be included under tables, but rather added into the text where applicable. The information should complement, but not duplicate the text. Use one horizontal line under the title, a second under column heads, and a third below the Table, above any footnotes. Vertical and italic lines should be omitted.

Notes in tables and illustrations

Data that are not statistically significant should not be noted. ^a $P < 0.05$, ^b $P < 0.01$ should be noted ($P > 0.05$ should not be noted). If there are other series of P values, ^c $P < 0.05$ and ^d $P < 0.01$ are used. A third series of P values can be expressed as ^e $P < 0.05$ and ^f $P < 0.01$. Other notes in tables or under illustrations should be expressed as ¹F, ²F, ³F; or sometimes as other symbols with a superscript (Arabic numerals) in the upper left corner. In a multi-curve illustration, each curve should be labeled with ●, ○, ■, □, ▲, △, etc., in a certain sequence.

Acknowledgments

Brief acknowledgments of persons who have made genuine contributions to the manuscript and who endorse the data and conclusions should be included. Authors are responsible for obtaining written permission to use any copyrighted text and/or illustrations.

REFERENCES

Coding system

The author should number the references in Arabic numerals according to the citation order in the text. Put reference numbers in square brackets in superscript at the end of citation content or after the cited author's name. For citation content which is part of the narration, the coding number and square brackets should be typeset normally. For example, "Crohn's disease (CD) is associated with increased intestinal permeability^[1,2]". If references are cited directly in the text, they should be put together within the text, for example, "From references^[19,22-24], we know that..."

When the authors write the references, please ensure that the order in text is the same as in the references section, and also ensure the spelling accuracy of the first author's name. Do not list the same citation twice.

PMID and DOI

Please provide PubMed citation numbers to the reference list, e.g. PMID and DOI, which can be found at <http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed> and <http://www.crossref.org/SimpleTextQuery/>, respectively. The numbers will be used in E-version of this journal.

Style for journal references

Authors: the name of the first author should be typed in bold-faced letters. The family name of all authors should be typed with the initial letter capitalized, followed by their abbreviated first and middle initials. (For example, Lian-Sheng Ma is abbreviated as Ma LS, Bo-Rong Pan as Pan BR). The title of the cited article and italicized journal title (journal title should be in its abbreviated form as shown in PubMed), publication date, volume number (in black), start page, and end page [PMID: 11819634 DOI: 10.3748/wjg.13.5396].

Style for book references

Authors: the name of the first author should be typed in bold-faced letters. The surname of all authors should be typed with the initial letter capitalized, followed by their abbreviated middle and first initials. (For example, Lian-Sheng Ma is abbreviated as Ma LS, Bo-Rong Pan as Pan BR) Book title. Publication number. Publication place: Publication press, Year: start page and end page.

Format

Journals

English journal article (list all authors and include the PMID where applicable)

- 1 **Jung EM**, Clevert DA, Schreyer AG, Schmitt S, Rennert J, Kubale R, Feuerbach S, Jung F. Evaluation of quantitative contrast harmonic imaging to assess malignancy of liver tumors:

A prospective controlled two-center study. *World J Gastroenterol* 2007; **13**: 6356-6364 [PMID: 18081224 DOI: 10.3748/wjg.13.6356]

Chinese journal article (list all authors and include the PMID where applicable)

- 2 **Lin GZ**, Wang XZ, Wang P, Lin J, Yang FD. Immunologic effect of Jianpi Yishen decoction in treatment of Pixu-diarhoea. *Shijie Huaren Xiaobua Zazhi* 1999; **7**: 285-287

In press

- 3 **Tian D**, Araki H, Stahl E, Bergelson J, Kreitman M. Signature of balancing selection in Arabidopsis. *Proc Natl Acad Sci USA* 2006; In press

Organization as author

- 4 **Diabetes Prevention Program Research Group**. Hypertension, insulin, and proinsulin in participants with impaired glucose tolerance. *Hypertension* 2002; **40**: 679-686 [PMID: 12411462 PMID:2516377 DOI:10.1161/01.HYP.0000035706.28494.09]

Both personal authors and an organization as author

- 5 **Vallancien G**, Emberton M, Harving N, van Moorselaar RJ; Alf-One Study Group. Sexual dysfunction in 1, 274 European men suffering from lower urinary tract symptoms. *J Urol* 2003; **169**: 2257-2261 [PMID: 12771764 DOI:10.1097/01.ju.0000067940.76090.73]

No author given

- 6 21st century heart solution may have a sting in the tail. *BMJ* 2002; **325**: 184 [PMID: 12142303 DOI:10.1136/bmj.325.7357.184]

Volume with supplement

- 7 **Geraud G**, Spierings EL, Keywood C. Tolerability and safety of frovatriptan with short- and long-term use for treatment of migraine and in comparison with sumatriptan. *Headache* 2002; **42** Suppl 2: S93-99 [PMID: 12028325 DOI:10.1046/j.1526-4610.42.s2.7.x]

Issue with no volume

- 8 **Banit DM**, Kaufer H, Hartford JM. Intraoperative frozen section analysis in revision total joint arthroplasty. *Clin Orthop Relat Res* 2002; (**401**): 230-238 [PMID: 12151900 DOI:10.1097/00003086-200208000-00026]

No volume or issue

- 9 Outreach: Bringing HIV-positive individuals into care. *HRS-A Careaction* 2002; 1-6 [PMID: 12154804]

Books

Personal author(s)

- 10 **Sherlock S**, Dooley J. Diseases of the liver and biliary system. 9th ed. Oxford: Blackwell Sci Pub, 1993: 258-296

Chapter in a book (list all authors)

- 11 **Lam SK**. Academic investigator's perspectives of medical treatment for peptic ulcer. In: Swabb EA, Azabo S. Ulcer disease: investigation and basis for therapy. New York: Marcel Dekker, 1991: 431-450

Author(s) and editor(s)

- 12 **Breedlove GK**, Schorfheide AM. Adolescent pregnancy. 2nd ed. Wicczorek RR, editor. White Plains (NY): March of Dimes Education Services, 2001: 20-34

Conference proceedings

- 13 **Harnden P**, Joffe JK, Jones WG, editors. Germ cell tumours V. Proceedings of the 5th Germ cell tumours Conference; 2001 Sep 13-15; Leeds, UK. New York: Springer, 2002: 30-56

Conference paper

- 14 **Christensen S**, Oppacher F. An analysis of Koza's computational effort statistic for genetic programming. In: Foster JA, Lutton E, Miller J, Ryan C, Tettamanzi AG, editors. Genetic programming. EuroGP 2002: Proceedings of the 5th European Conference on Genetic Programming; 2002 Apr 3-5; Kinsdale, Ireland. Berlin: Springer, 2002: 182-191

Electronic journal (list all authors)

- 15 Morse SS. Factors in the emergence of infectious diseases.

Emerg Infect Dis serial online, 1995-01-03, cited 1996-06-05; 1(1): 24 screens. Available from: URL: <http://www.cdc.gov/ncidod/eid/index.htm>

Patent (list all authors)

- 16 **Pagedas AC**, inventor; Ancel Surgical R&D Inc., assignee. Flexible endoscopic grasping and cutting device and positioning tool assembly. United States patent US 20020103498. 2002 Aug 1

Statistical data

Write as mean \pm SD or mean \pm SE.

Statistical expression

Express *t* test as *t* (in italics), *F* test as *F* (in italics), chi square test as χ^2 (in Greek), related coefficient as *r* (in italics), degree of freedom as *v* (in Greek), sample number as *n* (in italics), and probability as *P* (in italics).

Units

Use SI units. For example: body mass, *m* (B) = 78 kg; blood pressure, *p* (B) = 16.2/12.3 kPa; incubation time, *t* (incubation) = 96 h, blood glucose concentration, *c* (glucose) 6.4 ± 2.1 mmol/L; blood CEA mass concentration, *p* (CEA) = 8.6 24.5 μ g/L; CO₂ volume fraction, 50 mL/L CO₂, not 5% CO₂; likewise for 40 g/L formaldehyde, not 10% formalin; and mass fraction, 8 ng/g, *etc.* Arabic numerals such as 23, 243, 641 should be read 23 243 641.

The format for how to accurately write common units and quantum numbers can be found at: http://www.wjgnet.com/2218-6255/g_info_20100725065142.htm.

Abbreviations

Standard abbreviations should be defined in the abstract and on first mention in the text. In general, terms should not be abbreviated unless they are used repeatedly and the abbreviation is helpful to the reader. Permissible abbreviations are listed in Units, Symbols and Abbreviations: A Guide for Biological and Medical Editors and Authors (Ed. Baron DN, 1988) published by The Royal Society of Medicine, London. Certain commonly used abbreviations, such as DNA, RNA, HIV, LD50, PCR, HBV, ECG, WBC, RBC, CT, ESR, CSF, IgG, ELISA, PBS, ATP, EDTA, mAb, can be used directly without further explanation.

Italics

Quantities: *t* time or temperature, *c* concentration, *A* area, *l* length, *m* mass, *V* volume.

Genotypes: *gyrA*, *arg 1*, *c myc*, *c fos*, *etc.*

Restriction enzymes: *EcoRI*, *HindI*, *BamHI*, *Kho I*, *Kpn I*, *etc.*

Biology: *H. pylori*, *E. coli*, *etc.*

Examples for paper writing

All types of articles' writing style and requirement will be found in the link: <http://www.wjgnet.com/esps/NavigationInfo.aspx?id=15>

RESUBMISSION OF THE REVISED MANUSCRIPTS

Authors must revise their manuscript carefully according to the revision policies of Baishideng Publishing Group Co., Limited. The revised version, along with the signed copyright transfer agreement, responses to the reviewers, and English language Grade A certificate (for non-native speakers of English), should be submitted to the online system *via* the link contained in the e-mail sent by the editor. If you have any questions about the revision, please send e-mail to esps@wjgnet.com.

Language evaluation

The language of a manuscript will be graded before it is sent for revision. (1) Grade A: priority publishing; (2) Grade B: minor language polishing; (3) Grade C: a great deal of language polishing needed; and (4) Grade D: rejected. Revised articles should reach Grade A.

Copyright assignment form

Please download a Copyright assignment form from http://www.wjgnet.com/2218-6255/g_info_20100725065038.htm.

Responses to reviewers

Please revise your article according to the comments/suggestions provided by the reviewers. The format for responses to the reviewers' comments can be found at: http://www.wjgnet.com/2218-6255/g_info_20100725064808.htm.

Proof of financial support

For paper supported by a foundation, authors should provide a copy of the document and serial number of the foundation.

Links to documents related to the manuscript

WJR will be initiating a platform to promote dynamic interactions between the editors, peer reviewers, readers and authors. After a manuscript is published online, links to the PDF version of the submitted manuscript, the peer-reviewers' report and the revised manuscript will be put on-line. Readers can make comments on the peer reviewer's report, authors' responses to peer reviewers, and the revised manuscript. We hope that authors will benefit from this feedback and be able to revise the manuscript accordingly in a timely manner.

Publication fee

WJR is an international, peer-reviewed, OA online journal. Articles published by this journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium and format, provided the original work is properly cited. The use is non-commercial and is otherwise in compliance with the license. Authors of accepted articles must pay a publication fee. Publication fee: 600 USD per article. All invited articles are published free of charge.



百世登

Baishideng®

Published by **Baishideng Publishing Group Co., Limited**

Flat C, 23/F., Lucky Plaza,

315-321 Lockhart Road, Wan Chai, Hong Kong, China

Fax: +852-65557188

Telephone: +852-31779906

E-mail: bpgoffice@wjgnet.com

<http://www.wjgnet.com>

